Navigation Links
Orexigen Therapeutics to Present at Upcoming Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:
February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:
February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Corporate Contacts: OrexigenOrexigen

MediaJay Hagan

Denise PowellChief Business Officer

WCG(858) 875-8673

(510) 703-9491 


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... The Center for Excellence in Education (CEE) ... school teachers on Wednesday February 10, 2016. This Bite of Science session, hosted ... Conservation, located at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
Breaking Biology Technology:
(Date:1/8/2016)... , January 8, 2016 NXTD ... and WorldVentures ® , a privately held leading direct ... Inc. 5000 fastest-growing company announced that on ... of $2 million in Nxt-ID to develop a proprietary ... Nxt-ID,s Wocket ® , a unique smart wallet that ...
(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
(Date:1/6/2016)... , Jan. 6, 2016  Varam Capital, a ... their trusted partner to deliver advanced authentication solutions to ... services to the poor. A loan of a few ... lives, giving them the ability to purchase livestock or ... make clothing, or stock for a local store. ...
Breaking Biology News(10 mins):